Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/48771
Title: | Lullaby of Bromo-Dragonfly |
Authors: | Muscat, Michelle |
Keywords: | Hallucinogenic drugs -- Physiological effect Hallucinogenic drugs -- Research |
Issue Date: | 2019 |
Publisher: | Medical Portals Ltd. |
Citation: | Muscat, M. (2019). Lullaby of Bromo-Dragonfly. The Synapse : the Medical Professionals' Network, 18(3), 19. |
Abstract: | Bromo-Dragonfly, also called bromo-benzodifuranil-isopropylamine, is a psychedelic designer drug synthesized by Matthew A. Parker in the laboratory of David E. Nichols at Purdue University in 1998. This drug was first synthesized as a new research probe to investigate central nervous system serotonin receptor structure and activity. Although it was not originally intended for human consumption, it has subsequently been used for recreational purposes. It is a powerful 5-HT2A receptor agonist. This benzodifuran derivative is a strong hallucinogen, similar to LSD but with prolonged duration of action and possible intense hallucination visuals. Heterogeneous effects amongst individuals may be experienced even with the same dose. Overall it is said to be a third as potent as LSD on a weight for weight basis. The drug inhibits monoamine oxidase A. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/48771 |
Appears in Collections: | The Synapse, Volume 18, Issue 3 The Synapse, Volume 18, Issue 3 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
TheSynapse18(3)A4.pdf | 404.14 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.